Plasma extracellular vesicle proteins as promising noninvasive biomarkers for diagnosis of idiopathic pulmonary fibrosis
Sitaramaraju Adduri(The University of Texas Health Science Center at Tyler), Nagarjun V. Konduru(The University of Texas Health Science Center at Tyler), Sujith V. Cherian(The University of Texas Health Science Center), Daniela Nicastro(Southwestern Medical Center), Gary M. Hunninghake(Hubei University of Science and Technology), Noboru Hattori(Hiroshima University), Maria A. Planchart Ferretto(Brigham and Women's Hospital), Iván O. Rosas(Brigham and Women's Hospital), Fernando Poli de Frias(Brigham and Women's Hospital), Hiroshi Iwamoto(Hiroshima University), Anthony H. Maeda(Brigham and Women's Hospital), Sergio Poli(Brigham and Women's Hospital), Kevin F. Gibson(University of Pittsburgh), Daniel J. Kass(University of Pittsburgh), Karen Velasco‐Alzate(The University of Texas Health Science Center at Tyler), Sreerama Shetty(The University of Texas Health Science Center at Tyler), Jeffrey W. Miller(Harvard University), Ravikiran Vasireddy(The University of Texas Health Science Center at Tyler), Yasushi Horimasu(Hiroshima University), Lynette M. Sholl(Brigham and Women's Hospital), Kai Cai(The University of Texas Southwestern Medical Center), Li Li(Unknown), David A. Schwartz(Perinatal Institute), Zhe Chen, Harrison Ndetan(The University of Texas Health Science Center at Tyler), Yingze Zhang(Hebei Medical University), Anoop K. Pal(Cambridge Systematics (United States))
Cited by 9
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Toll-like Receptor 4 Polymorphisms and Atherogenesis
|New England Journal of Medicine|2002|1k
Muc5b is required for airway defence
|Nature|2013|777